AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure

AdvanCell announced it closed an oversubscribed $315 million Series D financing to advance its targeted alpha therapies development. The larger-than-expected demand (oversubscription) is a positive funding signal, though likely limited immediate market impact given it’s pre-IPO private financing.

Analysis

AdvanCell announced it closed an oversubscribed $315 million Series D financing to advance its targeted alpha therapies development. The larger-than-expected demand (oversubscription) is a positive funding signal, though likely limited immediate market impact given it’s pre-IPO private financing.